Olema Pharmaceuticals, Inc. — Form 8-K Summary
Reporting date: October 13, 2023; the report was signed and furnished with a press release dated October 17, 2023. The filing concerns corporate governance and director compensation, not quarterly or annual financial results.
Business Context and Reporting Period
Olema Pharmaceuticals, Inc. is a Delaware corporation headquartered in San Francisco, California, with common stock trading on Nasdaq under the symbol OLMA. The filing reports the appointment of Scott Garland to the company’s Board of Directors and Compensation Committee.
Financial and Other Key Metrics
- The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other operating financial metrics.
- Mr. Garland will receive an annual cash retainer of $40,000, plus committee retainers, including $6,000 for service on the Compensation Committee.
- He received a nonstatutory stock option for 21,520 shares, vesting in 36 equal monthly installments over three years.
- He also received a nonstatutory stock option for 14,347 shares, vesting in equal monthly installments through the company’s 2024 annual meeting, subject to continued service.
- Future annual equity compensation includes a nonstatutory stock option for 21,520 shares.
Material Changes and Governance Actions
- Scott Garland was appointed as a Class III director, effective October 16, 2023, with a term expected to expire at the 2026 annual meeting.
- The Board appointed Mr. Garland to the Compensation Committee effective the same date.
- The Board determined that Mr. Garland is independent under Nasdaq requirements.
- The filing states there are no arrangements or understandings related to his selection and no reportable related-party transactions under Item 404(a) of Regulation S-K.
- Olema entered into its standard indemnification agreement with Mr. Garland.
Guidance, Outlook, Risks, and Unusual Items
The filing provides no financial guidance, business outlook, operating risk update, contingencies, or clinical-development update. The principal economic effects disclosed are the director compensation commitments and equity awards, which may result in future stock-based compensation expense and share dilution; the filing does not quantify either impact.
The text states that the appointment was effective October 16, 2203, which appears to be a typographical error; the intended year is likely 2023 based on the filing date and surrounding disclosures.
Important Facts to Verify
- Confirm the effective date of Mr. Garland’s appointment, particularly the apparent “2203” typographical error.
- Review the applicable option agreements for exercise prices, expiration dates, vesting terms, and potential acceleration provisions.
- Assess the aggregate dilution and stock-based compensation impact of the director awards and future annual equity awards.
- Review Exhibit 99.1, the October 17, 2023 press release, for additional biographical or governance information.
- Consult the company’s subsequent filings for changes to Board composition, committee assignments, or director compensation.